| Literature DB >> 36112246 |
Jamal Nazari1, Ali Motie Nasrabadi2, Mohammad Bagher Menhaj3, Somayeh Raiesdana3.
Abstract
Epileptic seizures prediction and timely alarms allow the patient to take effective and preventive actions. In this paper, a convolutional neural network (CNN) is proposed to diagnose the preictal period. Our goal is for those epileptic patients in whom seizures occur late and it is very challenging to record the preictal signal for them. In the previous works, generalized methods were inevitably used for this group of patients which were not very accurate. Our approach to solve this problem is to provide a few-shot learning method. This method, having the previous knowledge, is trained with only a small number of samples, learns new tasks and reduces the efforts to collect more data. Evaluation results for three patients from the CHB-MIT database, for a 10-min seizure prediction horizon (SPH) and a 20-min seizure occurrence period (SOP), averaged sensitivity of 95.70% and a false prediction rate (FPR) of 0.057/h and for the 5-min prediction horizon and the 25-min seizure occurrence period averaged sensitivity of 98.52% and a false prediction rate of (FPR) of 0.045/h. The proposed few-shot learning method, based on previous knowledge gained from the generalizable method, is regulated with a few new patient samples for the patient. Our results show that the accuracy obtained in this method is higher than the generalizable methods.Entities:
Keywords: CNN; EEG; Epilepsy; Few-shot learning; Seizure prediction
Year: 2022 PMID: 36112246 PMCID: PMC9481757 DOI: 10.1186/s40708-022-00170-8
Source DB: PubMed Journal: Brain Inform ISSN: 2198-4026
Fig. 1Preictal intervals used in Trial 1 and Trial 2
Fig. 2Proposed generalizable method
Fig. 3Proposed method block diagram
Test results of the generalizable method for Trial 1 (SOP = 25 min, SPH = 5 min)
| Patient name | Fully connected | SVM | ||||
|---|---|---|---|---|---|---|
| Sensitivity (%) | FPR (/h) | AUC | Sensitivity (%) | FPR (/h) | AUC | |
| Chb01 | 94.09 ± 0.2 | 0.013 ± 0.001 | 0.954 ± 0.004 | 98.78 ± 0.7 | 0.011 ± 0.006 | 0.984 ± 0.002 |
| Chb02 | 50.00 ± 0.7 | 0.103 ± 0.006 | 0.901 ± 0.002 | 68.62 ± 0.1 | 0.100 ± 0.006 | 0.699 ± 0.004 |
| Chb04 | 95.45 ± 1.2 | 0.110 ± 0.005 | 0.967 ± 0.005 | 90.72 ± 0.2 | 0.097 ± 0.006 | 0.973 ± 0.005 |
| Chb05 | 71.36 ± 0.5 | 0.030 ± 0.009 | 0.786 ± 0.004 | 68.65 ± 0.4 | 0.121 ± 0.003 | 0.798 ± 0.003 |
| Chb06 | 100.00 ± 0.3 | 0.051 ± 0.002 | 0.984 ± 0.012 | 86.92 ± 0.8 | 0.041 ± 0.006 | 0.894 ± 0.001 |
| Chb07 | 81.54 ± 0.6 | 0.018 ± 0.005 | 0.912 ± 0.009 | 100.00 ± 0.0 | 0.023 ± 0.009 | 0.982 ± 0.007 |
| Chb09 | 82.91 ± 1.1 | 0.032 ± 0.004 | 0.891 ± 0.021 | 98.32 ± 0.1 | 0.110 ± 0.007 | 0.996 ± 0.002 |
| Chb14 | 62.98 ± 0.7 | 0.114 ± 0.006 | 0.919 ± 0.004 | 71.82 ± 0.6 | 0.050 ± 0.001 | 0.957 ± 0.008 |
| Chb15 | 99.19 ± 0.7 | 0.023 ± 0.009 | 0.997 ± 0.007 | 90.02 ± 0.5 | 0.000 ± 0.006 | 0.949 ± 0.002 |
| Chb17 | 81.73 ± 0.9 | 0.083 ± 0.001 | 0.924 ± 0.006 | 86.49 ± 0.2 | 0.097 ± 0.005 | 0.934 ± 0.004 |
| Chb18 | 78.18 ± 1.4 | 0.112 ± 0.006 | 0.897 ± 0.001 | 71.22 ± 0.7 | 0.105 ± 0.002 | 0.798 ± 0.001 |
| Chb19 | 99.09 ± 0.6 | 0.017 ± 0.005 | 0.998 ± 0.002 | 91.64 ± 0.1 | 0.001 ± 0.004 | 0.929 ± 0.005 |
| Chb20 | 100.00 ± 0.8 | 0.040 ± 0.008 | 0.901 ± 0.007 | 89.84 ± 0.3 | 0.091 ± 0.001 | 0.897 ± 0.002 |
| Chb21 | 77.72 ± 1.2 | 0.110 ± 0.008 | 0.867 ± 0.020 | 89.81 ± 0.5 | 0.106 ± 0.002 | 0.928 ± 0.003 |
| Chb22 | 86.05 ± 0.1 | 0.135 ± 0.002 | 0.944 ± 0.001 | 98.10 ± 0.2 | 0.124 ± 0.006 | 0.967 ± 0.001 |
| Avg | 84.02 ± 0.7 | 0.066 ± 0.005 | 0.922 ± 0.007 | 86.73 ± 0.3 | 0.071 ± 0.004 | 0.912 ± 0.003 |
Test results of the generalizable method for Trial 2 (SOP = 20 min, SPH = 10 min)
| Patient name | Fully connected | SVM | ||||
|---|---|---|---|---|---|---|
| Sensitivity (%) | FPR (/h) | AUC | Sensitivity (%) | FPR (/h) | AUC | |
| Chb01 | 92.12 ± 0.3 | 0.024 ± 0.003 | 0.933 ± 0.005 | 95.84 ± 0.6 | 0.036 ± 0.005 | 0.969 ± 0.001 |
| Chb02 | 83.05 ± 0.2 | 0.151 ± 0.002 | 0.891 ± 0.004 | 85.36 ± 0.2 | 0.120 ± 0.002 | 0.874 ± 0.005 |
| Chb04 | 93.87 ± 0.4 | 0.090 ± 0.004 | 0.958 ± 0.005 | 91.25 ± 0.4 | 0.087 ± 0.005 | 0.984 ± 0.005 |
| Chb05 | 75.54 ± 0.4 | 0.098 ± 0.002 | 0.892 ± 0.001 | 79.44 ± 0.5 | 0.134 ± 0.001 | 0.718 ± 0.002 |
| Chb06 | 91.89 ± 0.7 | 0.097 ± 0.005 | 0.943 ± 0.015 | 100.00 ± 0.4 | 0.097 ± 0.005 | 0.997 ± 0.006 |
| Chb07 | 83.35 ± 0.2 | 0.089 ± 0.001 | 0.907 ± 0.001 | 90.12 ± 0.1 | 0.114 ± 0.004 | 0.921 ± 0.004 |
| Chb09 | 79.88 ± 0.6 | 0.087 ± 0.006 | 0.851 ± 0.007 | 88.52 ± 0.7 | 0.210 ± 0.003 | 0.864 ± 0.003 |
| Chb14 | 95.18 ± 0.2 | 0.044 ± 0.005 | 0.912 ± 0.005 | 90.66 ± 0.6 | 0.077 ± 0.008 | 0.943 ± 0.004 |
| Chb15 | 91.22 ± 0.1 | 0.073 ± 0.002 | 0.945 ± 0.006 | 91.65 ± 0.3 | 0.034 ± 0.001 | 0.951 ± 0.001 |
| Chb17 | 67.83 ± 0.1 | 0.094 ± 0.001 | 0.902 ± 0.001 | 81.80 ± 0.1 | 0.058 ± 0.002 | 0.974 ± 0.005 |
| Chb18 | 71.91 ± 0.5 | 0.124 ± 0.003 | 0.825 ± 0.003 | 75.41 ± 0.2 | 0.165 ± 0.005 | 0.795 ± 0.004 |
| Chb19 | 94.02 ± 0.4 | 0.072 ± 0.004 | 0.976 ± 0.005 | 92.83 ± 0.1 | 0.084 ± 0.002 | 0.988 ± 0.002 |
| Chb20 | 87.20 ± 0.2 | 0.079 ± 0.001 | 0.895 ± 0.002 | 88.25 ± 0.0 | 0.088 ± 0.003 | 0.926 ± 0.003 |
| Chb21 | 70.98 ± 0.7 | 0.205 ± 0.002 | 0.798 ± 0.009 | 80.00 ± 0.4 | 0.211 ± 0.001 | 0.897 ± 0.005 |
| Chb22 | 90.11 ± 0.2 | 0.121 ± 0.003 | 0.951 ± 0.002 | 96.23 ± 0.1 | 0.099 ± 0.002 | 0.943 ± 0.006 |
| Avg | 83.94 ± 0.3 | 0.087 ± 0.003 | 0.905 ± 0.004 | 88.49 ± 0.3 | 0.114 ± 0.003 | 0.916 ± 0.004 |
Test results of the few-shot learning method for Trial 1 (SOP = 25 min, SPH = 5 min)
| Patient name | Fully connected | SVM | ||||
|---|---|---|---|---|---|---|
| Sensitivity (%) | FPR (/h) | AUC | Sensitivity (%) | FPR (/h) | AUC | |
| Chb03 | 96.18 ± 0.1 | 0.086 ± 0.006 | 0.963 ± 0.003 | 100.00 ± 0.5 | 0.056 ± 0.002 | 0.990 ± 0.003 |
| Chb10 | 94.90 ± 0.4 | 0.061 ± 0.007 | 0.988 ± 0.001 | 95.76 ± 0.6 | 0.079 ± 0.001 | 0.984 ± 0.002 |
| Chb16 | 98.54 ± 0.7 | 0.019 ± 0.006 | 0.984 ± 0.006 | 99.82 ± 0.4 | 0.000 ± 0.004 | 0.996 ± 0.005 |
| Avg | 96.54 ± 0.4 | 0.055 ± 0.006 | 0.978 ± 0.003 | 98.52 ± 0.5 | 0.045 ± 0.002 | 0.990 ± 0.003 |
Test results of the few-shot learning method for Trial 2 (SOP = 20 min, SPH = 10 min)
| Patient name | Fully connected | SVM | ||||
|---|---|---|---|---|---|---|
| Sensitivity (%) | FPR (/h) | AUC | Sensitivity (%) | FPR (/h) | AUC | |
| Chb03 | 94.18 ± 0.2 | 0.066 ± 0.001 | 0.944 ± 0.007 | 95.92 ± 0.1 | 0.070 ± 0.006 | 0.989 ± 0.003 |
| Chb10 | 90.10 ± 0.8 | 0.069 ± 0.006 | 0.908 ± 0.002 | 93.42 ± 0.7 | 0.101 ± 0.005 | 0.975 ± 0.004 |
| Chb16 | 92.24 ± 0.6 | 0.080 ± 0.002 | 0.937 ± 0.003 | 97.78 ± 0.5 | 0.002 ± 0.002 | 0.986 ± 0.002 |
| Avg | 92.17 ± 0.5 | 0.071 ± 0.003 | 0.929 ± 0.004 | 95.70 ± 0.4 | 0.057 ± 0.004 | 0.983 ± 0.003 |
Fig. 4Sensitivity chart for three CHB–MIT patients with different methods and trials. (G3 = Generalizable method for patient Chb03, FSL3 = FSL method for patient Chb03)
Comparison of the results of the state-of-the-art
| Authors | Method | Database | Sensitivity (%) | FPR(/h) | SOP(min) | SPH(sec) |
|---|---|---|---|---|---|---|
| 2017 [ | Phase locking value + SVM | 23Chb | 82.44 | – | 5 | 0 |
| 2018 [ | Zero crossings, PSD + LSTM | 23Chb | 90 | 0.11–0.02 | 15–120 | 0 |
| 2018 [ | STFT + CNN | 13Chb | 81.4 | 0.16 | 30 | 300 |
| 2017[ | CSP + LDA | 24Chb | 89 | 0.39 | 120 | 0 |
| 2019 [ | spectral Power + 3DCNN | 16Chb | 85.7 | 0.096 | 60 | 0 |
| 2018 [ | Wavelet transform + CNN | 23Chb | 87.8 | 0.14 | 10 | 0 |
| 2019 [ | Raw EEG + Bi-LSTM | 22Chb | 99.72 | 0.004 | 60 | 0 |
| 2020 [ | CNN + ELM | 23Chb | 95.85 | 0.045 | – | – |
| 2021 [ | STFT + RDANet | 13 Chb | 89.33 | – | – | – |
| Raw EEG + CNN | 15Chb | 88.49 | 0.114 | 20–25 | 300–600 | |
In this work the evaluation results showed a mean sensitivity of 98.52% and FPR=0.045/h for the 5 minute prediction horizon and the 25 minute seizure occurrence period which is improved compared to previous works [7] with an equal forecast horizon